REFERENCES
1. Martin SS, Aday AW, Almarzooq ZI, et al. ; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. 2024 heart disease and stroke statistics: a report of US and Global Data From the American Heart Association. Circulation. 2024;149:e347-913.
2. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature. 2004;431:931-45.
3. O'Brien J, Hayder H, Zayed Y, Peng C. Overview of MicroRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol. 2018;9:402.
4. Zhang X, Wang W, Zhu W, et al. Mechanisms and functions of long non-coding RNAs at multiple regulatory levels. Int J Mol Sci. 2019;20:5573.
5. Samra M, Srivastava K. Non-coding RNA and their potential role in cardiovascular diseases. Gene. 2023;851:147011.
6. Hall IF, Climent M, Viviani Anselmi C, et al. rs41291957 controls miR-143 and miR-145 expression and impacts coronary artery disease risk. EMBO Mol Med. 2021;13:e14060.
7. Holdt LM, Teupser D. Long noncoding RNA ANRIL: lnc-ing genetic variation at the chromosome 9p21 locus to molecular mechanisms of atherosclerosis. Front Cardiovasc Med. 2018;5:145.
8. Xie Y, Qi H, Peng W, et al. SNPs in lncRNA KCNQ1OT1 modulate its expression and confer susceptibility to salt sensitivity of blood pressure in a Chinese han population. Nutrients. 2022;14:3990.
9. Mihajlovic M, Savic-veselinovic M, Farkic M, Zeljic K. MiR-146a gene variant rs2910164 might be associated with coronary in-stent restenosis risk: results from a pilot study and meta-analysis. Genetika. 2022;54:933-46.
10. Burd CE, Jeck WR, Liu Y, Sanoff HK, Wang Z, Sharpless NE. Expression of linear and novel circular forms of an INK4/ARF-associated non-coding RNA correlates with atherosclerosis risk. PLoS Genet. 2010;6:e1001233.
11. Congrains A, Kamide K, Oguro R, et al. Genetic variants at the 9p21 locus contribute to atherosclerosis through modulation of ANRIL and CDKN2A/B. Atherosclerosis. 2012;220:449-55.
12. Li Q, Peng W, Li H, Zhuang J, Luo X, Xu Y. Association of the single nucleotide polymorphism in chromosome 9p21 and chromosome 9q33 with coronary artery disease in Chinese population. BMC Cardiovasc Disord. 2017;17:255.
13. Bayoglu B, Yuksel H, Cakmak HA, Dirican A, Cengiz M. Polymorphisms in the long non-coding RNA CDKN2B-AS1 may contribute to higher systolic blood pressure levels in hypertensive patients. Clin Biochem. 2016;49:821-7.
14. Foco L, De Bortoli M, Del Greco M F, et al. Genomic and molecular evidence that the LncRNA DSP-AS1 modulates desmoplakin expression. Hum Genet. 2025;144:843-60.
15. Cuesta-Llavona E, Lorca R, Rolle V, et al. Association of the genetic variation in the long non-coding RNA FENDRR with the risk of developing hypertrophic cardiomyopathy. Life. 2022;12:818.
16. Shen Z, She Q. Association between the deletion allele of Ins/Del polymorphism (Rs145204276) in the promoter region of GAS5 with the risk of atherosclerosis. Cell Physiol Biochem. 2018;49:1431-43.
17. Huang J, Li M, Li J, et al. LncRNA H19 rs4929984 variant is associated with coronary artery disease susceptibility in han chinese female population. Biochem Genet. 2021;59:1359-80.
18. Gómez J, Lorca R, Reguero JR, et al. Genetic variation at the long noncoding RNA H19 gene is associated with the risk of hypertrophic cardiomyopathy. Epigenomics. 2018;10:865-73.
19. Martens L, Rühle F, Witten A, et al. A genetic variant alters the secondary structure of the lncRNA H19 and is associated with dilated cardiomyopathy. RNA Biol. 2021;18:409-15.
20. Sun D, Zhu Z, Zhang Y, et al. Relation of genetic polymorphisms in microRNAs with diastolic and systolic function in type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis. 2022;32:2877-82.
21. Liu Y, Ferguson JF, Xue C, et al. Tissue-specific RNA-Seq in human evoked inflammation identifies blood and adipose LincRNA signatures of cardiometabolic diseases. Arterioscler Thromb Vasc Biol. 2014;34:902-12.
22. Wahba AS, Ibrahim ME, Mesbah NM, Saleh SM, Abo-Elmatty DM, Mehanna ET. Serum LINC00305 expression and its genetic variant rs2850711 are associated with clinical and laboratory features of rheumatoid arthritis. Br J Biomed Sci. 2020;77:142-7.
23. Zhang W, Zeng B, Yang M, et al. ncRNAVar: a manually curated database for identification of noncoding RNA variants associated with human diseases. J Mol Biol. 2021;433:166727.
24. Wang G, Li Y, Peng Y, Tang J, Li H. Association of polymorphisms in MALAT1 with risk of coronary atherosclerotic heart disease in a Chinese population. Lipids Health Dis. 2018;17:75.
25. Yu H, Tu S, Shen C, et al. Effects of the lncRNA MALAT1 gene region rs664589 site mutation on acute myocardial infarction in Chinese han. Cell Mol Biol. 2024;70:119-27.
26. Curila K, Benesova L, Tomasov P, et al. Variants in miRNA regulating cardiac growth are not a common cause of hypertrophic cardiomyopathy. Cardiology. 2015;130:137-42.
27. Ohanian M, Humphreys DT, Anderson E, Preiss T, Fatkin D. A heterozygous variant in the human cardiac miR-133 gene, MIR133A2, alters miRNA duplex processing and strand abundance. BMC Genet. 2013;14:18.
28. Mahmoud RH, Hefzy EM, Shaker OG, et al. GAS5 rs2067079 and miR-137 rs1625579 functional SNPs and risk of chronic hepatitis B virus infection among Egyptian patients. Sci Rep. 2021;11:20014.
29. Wang Y, Wang X, Li Z, et al. Two single nucleotide polymorphisms (rs2431697 and rs2910164) of miR-146a are associated with risk of coronary artery disease. Int J Environ Res Public Health. 2017;14:514.
30. Yan W, Chen R, Zhao Y, Zhang X, Li X. MicroRNA-155-5p rs767649 polymorphism is associated with susceptibility to essential hypertension in the Chinese Tibetan population in the Gannan Area. Artery Res. 2025;31:70.
31. Fragoso JM, Ramírez-Bello J, Martínez-Ríos MA, et al. miR-196a2 (rs11614913) polymorphism is associated with coronary artery disease, but not with in-stent coronary restenosis. Inflamm Res. 2019;68:215-21.
32. Harper AR, Mayosi BM, Rodriguez A, et al. Common variation neighbouring micro-RNA 22 is associated with increased left ventricular mass. PLoS One. 2013;8:e55061.
33. Mirani Sargazi F, Alidadi A, Taheri H, et al. Functional miR29a gene polymorphism enhanced the risk of chronic kidney disease in an Iranian population: a preliminary case-control study and bioinformatics analyses. Meta Gene. 2020;25:100755.
34. Butrym A, Łacina P, Kuliczkowski K, Bogunia-Kubik K, Mazur G. Genetic variation of the gene coding for microRNA-204 (miR-204) is a risk factor in acute myeloid leukaemia. BMC Cancer. 2018;18:107.
35. Dorn GW 2nd, Matkovich SJ, Eschenbacher WH, Zhang Y. A human 3’ miR-499 mutation alters cardiac mRNA targeting and function. Circ Res. 2012;110:958-67.
36. Ding W, Li M, Sun T, et al. A polymorphism rs3746444 within the pre-miR-499 alters the maturation of miR-499-5p and its antiapoptotic function. J Cell Mol Med. 2018;22:5418-28.
37. Lin X, Steinberg S, Kandasamy SK, et al. Common miR-590 Variant rs6971711 Present only in African Americans reduces miR-590 biogenesis. PLoS One. 2016;11:e0156065.
38. Kucher AN, Nazarenko MS. Regulatory potential of noncoding RNAs Co-located with cardiomyopathy related genes. Russ J Genet. 2023;59:325-43.
39. Zaman S, Wasfy JH, Kapil V, et al. The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma. Lancet. 2025;405:1264-312.
40. Abbas M, Gaye A. Emerging roles of noncoding RNAs in cardiovascular pathophysiology. Am J Physiol Heart Circ Physiol. 2025;328:H603-21.
41. Borén J, Chapman MJ, Krauss RM, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41:2313-30.
42. Gu X, Liu H, Luo W, Wang X, Wang H, Li L. Di-2-ethylhexyl phthalate-induced miR-155-5p promoted lipid metabolism via inhibiting cAMP/PKA signaling pathway in human trophoblastic HTR-8/Svneo cells. Reprod Toxicol. 2022;114:22-31.
43. Qiu XK, Ma J. Alteration in microRNA-155 level correspond to severity of coronary heart disease. Scand J Clin Lab Invest. 2018;78:219-23.
44. Liu L, Tan L, Yao J, Yang L. Long non‑coding RNA MALAT1 regulates cholesterol accumulation in ox‑LDL‑induced macrophages via the microRNA‑17‑5p/ABCA1 axis. Mol Med Rep. 2020;21:1761-70.
45. Li Y, Zhang D, Zhang Y, et al. Association of lncRNA polymorphisms with triglyceride and total cholesterol levels among myocardial infarction patients in Chinese population. Gene. 2020;724:143684.
46. Ghanbari M, de Vries PS, de Looper H, et al. A genetic variant in the seed region of miR-4513 shows pleiotropic effects on lipid and glucose homeostasis, blood pressure, and coronary artery disease. Hum Mutat. 2014;35:1524-31.
47. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357-61.
48. Zhang L, Wang IC, Meng S, Xu J. miR-146a Decreases Inflammation and ROS Production in Aged Dermal Fibroblasts. Int J Mol Sci. 2024;25:6821.
49. Yang X, Ren Y, Li X, Xia L, Wan J. MiR-146a reduces inflammation in experimental pancreatitis via the TRAF6-NF-κB signaling pathway in mice. Immun Inflamm Dis. 2025;13:e70163.
50. Roldán V, Arroyo AB, Salloum-Asfar S, et al. Prognostic role of MIR146A polymorphisms for cardiovascular events in atrial fibrillation. Thromb Haemost. 2014;112:781-8.
51. Qiao XR, Zheng T, Xie Y, et al. MiR-146a rs2910164 (G/C) polymorphism is associated with the development and prognosis of acute coronary syndromes: an observational study including case control and validation cohort. J Transl Med. 2023;21:325.
52. Li X, Yu M, Han L, et al. LINC00305 represses miR-124 expression to trigger inflammatory insults in the presence of lipopolysaccharide. Artif Cells Nanomed Biotechnol. 2019;47:2352-60.
53. Yang J, Gu L, Guo X, et al. LncRNA ANRIL expression and ANRIL gene polymorphisms contribute to the risk of ischemic stroke in the Chinese han population. Cell Mol Neurobiol. 2018;38:1253-69.
54. Pan JX. LncRNA H19 promotes atherosclerosis by regulating MAPK and NF-kB signaling pathway. European Review for Medical and Pharmacological Sciences. 2017;21:322-8. Available from: https://www.europeanreview.org/wp/wp-content/uploads/322-328-LncRNA-H19-promotes-atherosclerosis-by-promoting-the-expression-of-p38-and-p65.pdf [Last accessed on 1 Jun 2026].
55. Rangrez AY, Massy ZA, Metzinger-Le Meuth V, Metzinger L. miR-143 and miR-145: molecular keys to switch the phenotype of vascular smooth muscle cells. Circ Cardiovasc Genet. 2011;4:197-205.
56. Wang Y, Jia H, Song J. Accurate classification of non-ischemic cardiomyopathy. Curr Cardiol Rep. 2023;25:1299-317.
57. Lee S, Vander Roest AS, Blair CA, et al. Incomplete-penetrant hypertrophic cardiomyopathy MYH7 G256E mutation causes hypercontractility and elevated mitochondrial respiration. Proc Natl Acad Sci U S A. 2024;121:e2318413121.
58. Greer-Short A, Greenwood A, Leon EC, et al. AAV9-mediated MYBPC3 gene therapy with optimized expression cassette enhances cardiac function and survival in MYBPC3 cardiomyopathy models. Nat Commun. 2025;16:2196.
59. Kim JM, Lim KS, Hong JS, Kang JH, Lee YS, Hong KC. A polymorphism in the porcine miR-208b is associated with microRNA biogenesis and expressions of SOX-6 and MYH7 with effects on muscle fibre characteristics and meat quality. Anim Genet. 2015;46:73-7.
60. Liu L, An X, Li Z, et al. The H19 long noncoding RNA is a novel negative regulator of cardiomyocyte hypertrophy. Cardiovasc Res. 2016;111:56-65.
61. Dong DL, Chen C, Huo R, et al. Reciprocal repression between microRNA-133 and calcineurin regulates cardiac hypertrophy: a novel mechanism for progressive cardiac hypertrophy. Hypertension. 2010;55:946-52.
62. Naderi N, Mohsen-Pour N, Nilipour Y, Pourirahim M, Maleki M, Kalayinia S. A novel heterozygous missense MYH7 mutation potentially causes an autosomal dominant form of myosin storage myopathy with dilated cardiomyopathy. BMC Cardiovasc Disord. 2023;23:487.
63. Ghahremani S, Kanwal A, Pettinato A, et al. CRISPR activation reverses haploinsufficiency and functional deficits caused by TTN truncation variants. Circulation. 2024;149:1285-97.
64. Verdonschot JAJ, Vanhoutte EK, Claes GRF, et al. A mutation update for the FLNC gene in myopathies and cardiomyopathies. Hum Mutat. 2020;41:1091-111.
65. Janz A, Chen R, Regensburger M, et al. Generation of two patient-derived iPSC lines from siblings (LIBUCi001-A and LIBUCi002-A) and a genetically modified iPSC line (JMUi001-A-1) to mimic dilated cardiomyopathy with ataxia (DCMA) caused by a homozygous DNAJC19 mutation. Stem Cell Res. 2020;46:101856.
66. Zheng QX, Wang J, Gu XY, et al. TTN-AS1 as a potential diagnostic and prognostic biomarker for multiple cancers. Biomed Pharmacother. 2021;135:111169.
67. Pimenta EM, Santos CGMD, Assis MGD, Veneroso CE, Soalheiro I, Serpa TKF. TTN-AS1 genotype (rs1001238) and its influence on inflammatory responses in muscle tissues in soccer players. Braz arch biol technol. 2024;67:e24231067.
68. Zhang X, Yuan S, Liu J, et al. Overexpression of cytosolic long noncoding RNA cytb protects against pressure-overload-induced heart failure via sponging microRNA-103-3p. Mol Ther Nucleic Acids. 2022;27:1127-45.
69. Zhang Y, Zhang M, Xu W, Chen J, Zhou X. The long non-coding RNA H19 promotes cardiomyocyte apoptosis in dilated cardiomyopathy. Oncotarget. 2017;8:28588-94.
70. Heliö K, Brandt E, Vaara S, et al. DSP c.6310delA p.(Thr2104Glnfs*12) associates with arrhythmogenic cardiomyopathy, increased trabeculation, curly hair, and palmoplantar keratoderma. Front Cardiovasc Med. 2023;10:1130903.
71. Yoon JH, Abdelmohsen K, Srikantan S, et al. LincRNA-p21 suppresses target mRNA translation. Mol Cell. 2012;47:648-55.
72. Piquer-Gil M, Domenech-Dauder S, Sepúlveda-Gómez M, Machí-Camacho C, Braza-Boïls A, Zorio E. Non coding RNAs as regulators of Wnt/β-catenin and hippo pathways in arrhythmogenic cardiomyopathy. Biomedicines. 2022;10:2619.
73. Wang J, Huang F, Shi Y, et al. RP11-323N12.5 promotes the malignancy and immunosuppression of human gastric cancer by increasing YAP1 transcription. Gastric Cancer. 2021;24:85-102.
74. Wu N, Yuan Z, Du KY, et al. Translation of yes-associated protein (YAP) was antagonized by its circular RNA via suppressing the assembly of the translation initiation machinery. Cell Death Differ. 2019;26:2758-73.
75. Connolly M, Garfield BE, Crosby A, Morrell NW, Wort SJ, Kemp PR. miR-1-5p targets TGF-βR1 and is suppressed in the hypertrophying hearts of rats with pulmonary arterial hypertension. PLoS One. 2020;15:e0229409.
76. Li JC, Jia J, Dong L, et al. Angiotensin II mediates hypertensive cardiac fibrosis via an Erbb4-IR-dependent mechanism. Mol Ther Nucleic Acids. 2023;33:180-90.
77. Zhu M, Li G, Li Y, Chen J. Circ_0005372 targets the miR-153-3p/ITGB3 axis to stimulate the PI3K/AKT signaling pathway to facilitate the occurrence and development of congenital heart disease and pulmonary arterial hypertension in children. Cardiovasc Pathol. 2026;80:107768.
78. Gurha P, Abreu-Goodger C, Wang T, et al. Targeted deletion of microRNA-22 promotes stress-induced cardiac dilation and contractile dysfunction. Circulation. 2012;125:2751-61.
79. E M, Ren F, Yu Y, Li H, Shen C. The role of lncRNAKCNQ1OT1/miR-301b/Tcf7 axis in cardiac hypertrophy. Cardiol Young. 2024;34:1493-505.
80. Zheng D, Hou Y, Li Y, et al. Long non-coding RNA Gas5 is associated with preeclampsia and regulates biological behaviors of trophoblast via MicroRNA-21. Front Genet. 2020;11:188.
81. Tang Y, Wang Y, Wang X, Liu Y, Zheng K. A genetic variant of rs145204276 in the promoter region of long noncoding RNA GAS5 is associated with a reduced risk of breast cancer. Clin Breast Cancer. 2019;19:e415-21.
82. Lampropoulos K, Penteris M, Gerotziafas G. Direct oral anticoagulants in valvular diseases and prosthetic valves: why not? Cardiovasc Drugs Ther. 2026;40:697-709.
83. Jiang Y, Zhu J, Chen Z, et al. CircRNA ARHGAP10 promotes osteogenic differentiation through the miR-335-3p/RUNX2 pathway in aortic valve calcification. J Thorac Dis. 2023;15:5971-91.
84. Yu C, Wu D, Zhao C, Wu C. CircRNA TGFBR2/MiR-25-3p/TWIST1 axis regulates osteoblast differentiation of human aortic valve interstitial cells. J Bone Miner Metab. 2021;39:360-71.
85. Yu C, Li L, Xie F, et al. LncRNA TUG1 sponges miR-204-5p to promote osteoblast differentiation through upregulating Runx2 in aortic valve calcification. Cardiovasc Res. 2018;114:168-79.
86. Xiao X, Zhou T, Guo S, et al. LncRNA MALAT1 sponges miR-204 to promote osteoblast differentiation of human aortic valve interstitial cells through up-regulating Smad4. Int J Cardiol. 2017;243:404-12.
87. Zheng D, Wang B, Zhu X, et al. LncRNA OIP5-AS1 inhibits osteoblast differentiation of valve interstitial cells via miR-137/TWIST11 axis. Biochem Biophys Res Commun. 2019;511:826-32.
88. McDonagh TA, Metra M, Adamo M, et al. ; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021;42:3599-726.
89. Triposkiadis F, Xanthopoulos A, Parissis J, Butler J, Farmakis D. Pathogenesis of chronic heart failure: cardiovascular aging, risk factors, comorbidities, and disease modifiers. Heart Fail Rev. 2022;27:337-44.
90. Yeung F, Chung E, Guess MG, Bell ML, Leinwand LA. Myh7b/miR-499 gene expression is transcriptionally regulated by MRFs and Eos. Nucleic Acids Res. 2012;40:7303-18.
91. Calore M, Lorenzon A, Vitiello L, et al. A novel murine model for arrhythmogenic cardiomyopathy points to a pathogenic role of Wnt signalling and miRNA dysregulation. Cardiovasc Res. 2019;115:739-51.
92. Baulina N, Pisklova M, Kiselev I, Chumakova O, Zateyshchikov D, Favorova O. Circulating miR-499a-5p is a potential biomarker of MYH7-associated hypertrophic cardiomyopathy. Int J Mol Sci. 2022;23:3791.
93. Gupta SK, Kumari S, Singh S, Barthwal MK, Singh SK, Thum T. Non-coding RNAs: regulators of valvular calcification. J Mol Cell Cardiol. 2020;142:14-23.
94. Corsten MF, Dennert R, Jochems S, et al. Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet. 2010;3:499-506.
95. Sang HQ, Jiang ZM, Zhao QP, Xin F. MicroRNA-133a improves the cardiac function and fibrosis through inhibiting Akt in heart failure rats. Biomed Pharmacother. 2015;71:185-9.
96. Chen CY, Choong OK, Liu LW, et al. MicroRNA let-7-TGFBR3 signalling regulates cardiomyocyte apoptosis after infarction. EBioMedicine. 2019;46:236-47.
97. Zhao Y, Yan M, Chen C, et al. MiR-124 aggravates failing hearts by suppressing CD151-facilitated angiogenesis in heart. Oncotarget. 2018;9:14382-96.
98. Dong M, Chen D, Zhu Y, et al. Impaired regulation of MMP2/16-MLCK3 by miR-146a-5p increased susceptibility to myocardial ischaemic injury in aging mice. Cardiovasc Res. 2023;119:786-801.
99. Ciccacci C, Di Fusco D, Cacciotti L, et al. MicroRNA genetic variations: association with type 2 diabetes. Acta Diabetol. 2013;50:867-72.
100. Khan MS, Rahman B, Haq TU, et al. Deciphering the variants located in the MIR196A2, MIR146A, and MIR423 with type-2 diabetes mellitus in Pakistani population. Genes. 2021;12:664.
101. Cheng J, Tang Y, Cai X, Gong J. Long noncoding RNAs testis development related gene 1 aggravates transforming growth factor-β1-induced fibrogenesis and inflammatory response of cardiac fibroblasts via miR-605-3p/tumor necrosis factor receptor superfamily-21 axis. J Cardiovasc Pharmacol. 2022;79:296-303.
102. Moudi M, Montazer Zohour M. SNP in microRNA sequences or binding sites of miRNAs: association with type 2 diabetes mellitus susceptibility and in silico analysis. Int J Diabetes Dev Ctries. 2018;38:330-7.
103. Zhang S, Yin Z, Dai FF, et al. miR-29a attenuates cardiac hypertrophy through inhibition of PPARδ expression. J Cell Physiol. 2019;234:13252-62.
104. Argirò A, Parikh V, Jurcut R, et al. Hypertrophic cardiomyopathy. Nat Rev Dis Primers. 2025;11:58.
105. Schultheiss HP, Fairweather D, Caforio ALP, et al. Dilated cardiomyopathy. Nat Rev Dis Primers. 2019;5:32.
106. Hamdani N, Kooij V, van Dijk S, et al. Sarcomeric dysfunction in heart failure. Cardiovasc Res. 2008;77:649-58.
107. Viola HM, Hool LC. Impaired calcium handling and mitochondrial metabolic dysfunction as early markers of hypertrophic cardiomyopathy. Arch Biochem Biophys. 2019;665:166-74.
108. Wang Y, Zhou T, Zhao J, et al. Calcium handling remodeling in dilated cardiomyopathy: From molecular mechanisms to targeted therapies. Channels. 2025;19:2519545.
109. Wang JG, Palmer BF, Vogel Anderson K, Sever P. Amlodipine in the current management of hypertension. J Clin Hypertens. 2023;25:801-7.
110. Redel-Traub G, Marx SO, Marks AR. Targeting calcium regulation for heart failure and arrhythmia therapeutics: a critical review. Circulation. 2025;152:957-70.
111. Letonja J, Petrovič D, Petrovič D. CDKN2B-AS1 polymorphism rs1333049 is associated with advanced carotid artery atherosclerosis in a Slovenian population. Biomol Biomed. 2025;25:1362-8.
112. Gao W, Zhu M, Wang H, et al. Association of polymorphisms in long non-coding RNA H19 with coronary artery disease risk in a Chinese population. Mutat Res. 2015;772:15-22.
113. Oner T, Arslan C, Yenmis G, et al. Association of NFKB1A and microRNAs variations and the susceptibility to atherosclerosis. J Genet. 2017;96:251-9.
114. Bao Q, Li R, Wang C, et al. Association between microRNA-146a rs2910164 polymorphism and coronary heart disease: an updated meta-analysis. Medicine. 2022;101:e31860.
115. Ali S, Haq TU, Hussain M, et al. Genetic variants rs2910164, rs4636297 and rs895819 may contribute to the onset of acute myocardial infarction in Pakistani population. PLoS One. 2024;19:e0296025.
116. Zhang Z, Xu G, Cai B, Zhang H, Zhu W, Liu X. Genetic variants in MicroRNAs predict recurrence of ischemic stroke. Mol Neurobiol. 2017;54:2776-80.
117. Gao P, Xia JH, Sipeky C, et al. ; PRACTICAL Consortium. Biology and clinical implications of the 19q13 aggressive prostate cancer susceptibility locus. Cell. 2018;174:576-589.e18.
118. Yin D, Hu ZQ, Luo CB, et al. LINC01133 promotes hepatocellular carcinoma progression by sponging miR-199a-5p and activating annexin A2. Clin Transl Med. 2021;11:e409.
119. Yang Q, Jie Z, Ye S, et al. Genetic variations in miR-27a gene decrease mature miR-27a level and reduce gastric cancer susceptibility. Oncogene. 2014;33:193-202.
120. Xu C, Liu M, Jia D, Tao T, Hao D. lncRNA TINCR SNPs and expression levels are associated with bladder cancer susceptibility. Genet Test Mol Biomarkers. 2021;25:31-41.
121. Yu J, Yang Y, Xu Z, et al. Long noncoding RNA ahit protects against cardiac hypertrophy through SUZ12 (suppressor of zeste 12 protein homolog)-mediated downregulation of MEF2A (myocyte enhancer factor 2A). Circ Heart Fail. 2020;13:e006525.
122. Liu L, Zhang D, Li Y. LncRNAs in cardiac hypertrophy: from basic science to clinical application. J Cell Mol Med. 2020;24:11638-45.
123. Samani NJ, Erdmann J, Hall AS, et al. ; WTCCC and the Cardiogenics Consortium. Genomewide association analysis of coronary artery disease. N Engl J Med. 2007;357:443-53.
124. Rodríguez-Esparragón F, Torres-Mata LB, Cazorla-Rivero SE, et al. Analysis of ANRIL isoforms and key genes in patients with severe coronary artery disease. Int J Mol Sci. 2023;24:16127.
125. Shi P, Tang B, Xie W, et al. LncRNA-induced lysosomal localization of NHE1 promotes increased lysosomal pH in macrophages leading to atherosclerosis. J Biol Chem. 2025;301:110246.
126. Zhu C, Baumgarten N, Wu M, et al. CVD-associated SNPs with regulatory potential reveal novel non-coding disease genes. Hum Genomics. 2023;17:69.
127. Fitzgerald K, White S, Borodovsky A, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376:41-51.
